Aim. This study reviewed four studies referenced after U-74389G (L) administration. Three studies concerned histologic variables for rat uteri, fallopian tubes and ovaries, respectively. Each organ was examined for four certain histologic variables, such as edema, karyorrhexis, congestion and inflammation (EKCI), in an induced ischemia reperfusion experiment. Furthermore, cytokine (TNF-α) and oxidant marker malondialdehyde (MDA) were calculated along with ovaries, whereas the associated fourth study concerned the serum spectrum. Materials and method. The two main experimental timepoints at which the EKCI variables of organs were examined, as well as the TNF-α and MDA scores and serum values were evaluated were the 60th reperfusion minute for two groups (A and C) and the 120th reperfusion minute for the other two groups (B and D). In particular, groups A and B were processed without drugs, whereas groups C and D were processed after the administration of U-74389G. Results. The preliminary studies showed that U-74389G has a nonsignificant deteriorating effect on uteri pathology within the “lesion alteration-free” score by 0.0758471 (0.1464624-0.2981566; p=0.4940), and also a nonsignificant deteriorating effect on fallopian tubes pathology within the “lesion alteration-free” score by 0.0073429 (0.0475001-0.0621858; p=0.7878), but a significant recession effect on ovarian pathology within the “lesion alteration-free” score by 0.1772727 (-0.3208232 – -0.0337223; p=0.0169). Valuable outcomes confirmed the above from the calculations performed for TNF-α and MDA scores, and the overall metabolic sign of the fourth study. Conclusions. U-74389G administration was significantly active only for ovarian pathology (p=0.0169), in accordance with the reduced TNF-α levels by 4.69% (±8.40%; p=0.5749), the significantly reduced MDA levels by 9.85% (±2.66%; p=0.0005), and the overall metabolic vector of the agent.
Tsompos et al. (2026) studied this question.